Homepage Top Section2

This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in this area. Arthrosi Therapeutics founder and

ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The

This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery and preclinical development

The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. This expedited review process is a significant step towards

The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prowess. The goal is to streamline and expedite the development and

Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50

BARDA is a part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services. The product, which represents $139.7m of the

Zurnai is indicated for treating suspected or known opioid overdose in adults and pediatric patients aged 12 years and older. It is not a substitute for emergency medical

One indication is for treating adults with priorly treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumours (pNET). Other one is for use in adults